Evaluation of permanent growth hormone deficiency (GHD) in young adults with childhood onset GHD: a multicenter study

J Clin Res Pediatr Endocrinol. 2008;1(1):30-7. doi: 10.4008/jcrpe.v1i1.7. Epub 2008 Aug 5.

Abstract

Background: Reconfirming the diagnosis of childhood onset growth hormone deficiency (GHD) in young adults is necessary to demonstrate the need for continuation of GH therapy.

Objective: This nationally-based study was planned to establish GH status during adulthood in childhood-onset GH deficient patients and to evaluate factors that would predict persistency of the GHD.

Methods: In this multicenter study, 70 GH deficient patients who had reached final height were evaluated after completion of GH treatment. Fifty-two patients (74%) had isolated GHD and 18 patients (26%) had multiple pituitary hormone deficiency (MPHD). Patients who had reached final height and the pubertal Tanner stage 5 were reevaluated for GH status. After at least 6 weeks of cessation of GH treatment, patients were retested with insulin induced hypoglycemia.

Results: GHD was found to be transient in 64.3% of all patients. Of the isolated GH deficient patients 82.7% had transient GHD, whereas 88.9% of the MPHD patients showed persistent GHD. Comparison of isolated GH deficient and multiple hormone deficient patients indicated higher peak GH, IGF-I and IGFBP-3 levels in isolated GH deficient patients. No parameter was significantly different in the transiently and persistently GH deficient patients with respect to gender. Although specificity of IGF-I value of less than -2 SD showing persistency of GHD was lower than the specificity of IGFBP-3 value of less than -2 SD (65.7% vs 84%), negative predictive values were similar for the two parameters (85.2% and 84%, respectively).

Conclusion: Most of the cases of childhood onset GHD are idiopathic and the GHD is transient. In patients with MPHD, GHD is generally permanent. Low IGF-I and IGFBP-3 levels are supporting findings to show persistency of the GHD.

Keywords: Growth hormone deficiency; childhood; retesting.

Publication types

  • Multicenter Study

MeSH terms

  • Age of Onset
  • Child
  • Dwarfism, Pituitary / blood*
  • Female
  • Human Growth Hormone / blood
  • Human Growth Hormone / deficiency*
  • Humans
  • Hypopituitarism / blood*
  • Insulin-Like Growth Factor Binding Protein 3 / deficiency
  • Insulin-Like Growth Factor I / deficiency
  • Male
  • Young Adult

Substances

  • Insulin-Like Growth Factor Binding Protein 3
  • Human Growth Hormone
  • Insulin-Like Growth Factor I